Travaux scientifiques

Doç. Dr. Emir Çelik

58 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15725-9 PMID 41691201 Texte intégral en libre accèsSource : OpenAlex

  2. Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study

    Cancer Management and Research, 2026

    DOI 10.2147/cmar.s583473 PMID 42038552 Texte intégral en libre accèsSource : OpenAlex

  3. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Therapeutic Advances in Medical Oncology, 2026

    DOI 10.1177/17588359261430583 PMID 41835339 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  4. Quality of Life and Healthcare Experiences of Patients with Anal Cancer: A Mixed-Methods Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33050266 PMID 42187583 Texte intégral en libre accèsSource : OpenAlex

  5. Prognostic factors and survival outcomes in older adults with extensive-stage small cell lung cancer: A multicenter retrospective cohort study

    Medicine, 2026

    DOI 10.1097/md.0000000000048711 PMID 42116366 Texte intégral en libre accèsSource : OpenAlex

  6. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Source : OpenAlex

  7. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Source : OpenAlex

  8. Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

    Cancers, 2026

    DOI 10.3390/cancers18071170 PMID 41976392 Texte intégral en libre accèsSource : OpenAlex

  9. The G8 tool for screening malnutrition before GLIM in geriatric cancer patients

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15977-5 PMID 41987111 Texte intégral en libre accèsSource : OpenAlex

  10. The healthcare experience of solid rare cancer patients and their healthcare professionals: quantitative results from the eortc qol rare cancer study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-17156-y Texte intégral en libre accèsSource : OpenAlex

  11. Impact of neuropathy severity on hand function, strength, and dexterity in patients with oxaliplatin-induced peripheral neuropathy

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16621-y PMID 42958115 Texte intégral en libre accèsSource : OpenAlex

  12. Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-29276-9 PMID 41315659 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  13. Factors affecting survival and prognosis in extensive stage small cell lung cancer

    BMC Pulmonary Medicine, 2025

    DOI 10.1186/s12890-025-03625-w PMID 40200252 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  14. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14134568 PMID 40648939 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  15. Comparison of clinical and prognostic characteristics of patients with classic and AIDS-related Kaposi sarcoma: A single-center experience

    Medicine, 2025

    DOI 10.1097/md.0000000000043576 PMID 40760592 Texte intégral en libre accèsSource : OpenAlex

  16. Distribution of side effects of anti-EGFR treatments in patients with metastatic colorectal cancer and evaluation of their relationship with survival

    Anti-Cancer Drugs, 2025

    DOI 10.1097/cad.0000000000001755 PMID 40626459 1 citation (Europe PMC) Source : OpenAlex

  17. Bevacizumab Efficacy and Tolerability in Patients with Metastatic Platinum-Sensitive Ovarian Cancer Beyond Progression

    Cancer Management and Research, 2025

    DOI 10.2147/cmar.s531276 PMID 40861079 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  18. The Effect of Total Neoadjuvant Treatment on Pathological Response and Survival in Locally Advanced Rectal Cancer: A Single Center Experience

    Clinical Colorectal Cancer, 2025

    DOI 10.1016/j.clcc.2025.05.001 PMID 40537334 1 citation (Europe PMC) Source : OpenAlex

  19. The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e20501 Texte intégral en libre accèsSource : OpenAlex

  20. Advancing prognostic precision in unplanned oncology admissions: the promise of the PROMISE–CTI score

    The Lancet Regional Health - Europe, 2025

    DOI 10.1016/j.lanepe.2025.101336 PMID 40530357 Texte intégral en libre accèsSource : OpenAlex

  21. Analysis of the impact of IMDC score parameters on patients with metastatic clear cell renal cell carcinoma

    Biomarkers in Medicine, 2025

    DOI 10.1080/17520363.2025.2589382 PMID 41243728 Source : OpenAlex

  22. HER2 POZITIF METASTATIK MEME KANSERLI HASTALARDA TRASTUZUMAB DERUXTECAN’IN GERÇEK YAŞAM VERILERI: TÜRK ONKOLOJI GRUBU ÇOK MERKEZLI ÇALIŞMASI

    Kocaeli Üniversitesi - AVESİS, 2025

    Source : OpenAlex

  23. Clinical Analysis of Multiple Primary Malignant Tumors: A Single-Center Experience

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25022 Texte intégral en libre accèsSource : OpenAlex

  24. Novel heterogeneity method for predicting survival in non-metastatic triple-negative breast cancer

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2025

    DOI 10.1016/j.remnie.2025.500112 PMID 39921170 Source : ORCID

  25. Nuevo método de heterogeneidad para predecir la supervivencia en el cáncer de mama triple negativo no metastásico

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2025.500112 Source : ORCID

  26. Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients

    Oncology, 2024

    DOI 10.1159/000540334 PMID 39008971 3 citations (Europe PMC) Source : OpenAlex

  27. Evaluation of ixabepilone efficacy and tolerability in metastatic breast cancer

    Medicine, 2024

    DOI 10.1097/md.0000000000040649 PMID 39809199 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  28. Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function

    Actas Urológicas Españolas (English Edition), 2024

    DOI 10.1016/j.acuroe.2024.04.002 PMID 38570033 Source : OpenAlex

  29. Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?

    Medicine, 2023

    DOI 10.1097/md.0000000000034014 PMID 37352081 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  30. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-03984-5 PMID 35381885 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  31. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_1104_21 PMID 36510987 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  32. Breast cancer to thyroid gland: An unconventional metastatic site

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_561_20 PMID 35900558 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  33. Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_1276_21 PMID 37313913 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  34. A single center's experience of the extrapulmonary neuroendocrine carcinomas

    Northern clinics of Istanbul, 2022

    DOI 10.14744/nci.2021.47887 PMID 35340315 1 citation (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  35. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2021

    DOI 10.1007/s00432-020-03501-6 PMID 33433657 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  36. The Relationship Between Symptom Severity and Caregiver Burden in Cancer Patients Under Palliative Care: A Cross-Sectional Study

    Journal of Palliative Care, 2021

    DOI 10.1177/08258597211045780 PMID 34672215 12 citations (Europe PMC) Source : OpenAlex

  37. Sarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumors

    European Geriatric Medicine, 2021

    DOI 10.1007/s41999-021-00592-3 PMID 34826111 4 citations (Europe PMC) Source : OpenAlex

  38. Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection

    Journal of Surgical Oncology, 2021

    DOI 10.1002/jso.26455 PMID 33684252 3 citations (Europe PMC) Source : OpenAlex

  39. The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID‐19 patients with malignancy: A single‐center experience

    Journal of Medical Virology, 2021

    DOI 10.1002/jmv.27123 PMID 34081337 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  40. Could Systemic İnflammation-Based Prognostic Scores Predict The Clinical Outcome in Patients with Breast Cancer Treated with Everolimus Plus Exemestane?

    Eurasian Journal of Medical Investigation, 2021

    DOI 10.14744/ejmi.2021.21203 1 citation (OpenAlex) Source : OpenAlex

  41. Risk of Malnutrition and Its Effects on the Quality of Life of Hospitalized Cancer Patients

    Namık Kemal Tıp Dergisi, 2021

    DOI 10.4274/nkmj.galenos.2021.02886 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  42. The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer

    Medical Oncology, 2021

    DOI 10.1007/s12032-021-01457-2 PMID 33452614 Source : OpenAlex

  43. Geriatri Kliniğinde Pnömoni Enfeksiyonu Nedeniyle Takip Edilen Hastaların Analizi ve Pnömokok Aşısının Prognoza Etkisi

    Sakarya Medical Journal, 2021

    DOI 10.31832/smj.779500 Texte intégral en libre accèsSource : OpenAlex

  44. PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)

    AYBU AVESIS, 2020

    Source : OpenAlex

  45. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas

    Growth Hormone & IGF Research, 2020

    DOI 10.1016/j.ghir.2020.101356 PMID 33010581 12 citations (Europe PMC) Source : OpenAlex

  46. Comparison of Attention for Cancer Research on Social Media Versus Academia: An Altmetric Score Analysis

    2020

    DOI 10.4999/uhod.204020 9 citations (OpenAlex) Source : OpenAlex

  47. The top 100 cited articles in lung cancer – a bibliometric analysis

    Współczesna Onkologia, 2020

    DOI 10.5114/wo.2020.94725 PMID 32514234 9 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  48. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer

    Tumori Journal, 2020

    DOI 10.1177/0300891620953468 PMID 32935638 4 citations (Europe PMC) Source : OpenAlex

  49. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma

    Melanoma Research, 2020

    DOI 10.1097/cmr.0000000000000678 PMID 32898388 7 citations (Europe PMC) Source : OpenAlex

  50. A rare case of cardiac toxicity in a patient with imatinib treatment: Case report

    Journal of Cancer Research and Therapeutics, 2020

    DOI 10.4103/jcrt.jcrt_188_19 PMID 35900559 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex